Download MendeleySubstituted diaryl ether compounds as retinoic acid-related orphan Receptor-gamma t (ROR gamma t) agonists.
Ruan, Z., Park, P.K., Wei, D., Purandare, A., Wan, H., O'Malley, D., Stachura, S., Perez, H., Cavallaro, C.L., Weigelt, C.A., Sack, J.S., Ruzanov, M., Khan, J., Gururajan, M., Wong, J.J., Huang, Y., Yarde, M., Li, Z., Chen, C., Sun, H., Borowski, V., Xie, J.H., Anthony, M., Agler, M., Fink, B.E., Harikrishnan, L.S.(2021) Bioorg Med Chem Lett 35: 127778-127778
- PubMed: 33422603
- DOI: https://doi.org/10.1016/j.bmcl.2021.127778
- Primary Citation of Related Structures:
7KXD, 7KXE, 7KXF - PubMed Abstract:
The discovery of a series of substituted diarylether compounds as retinoic acid related orphan receptor γt (RORγt) agonists is described. Compound 1 was identified from deck mining as a RORγt agonist. Hit-to-lead optimization led to the identification of lead compound 5, which possesses improved potency (10x). Extensive SAR exploration led to the identification of a potent and selective compound 22, that demonstrated an improved pharmacokinetic profile and a dose-dependent pharmacodynamic response. However, when dosed in a MC38 syngeneic tumor model, no evidence of efficacy was observed. ©2020 Elsevier Science Ltd. All rights reserved.
Organizational Affiliation:
Department of Chemistry, Bristol Myers Squibb Company, P.O. Box 4000, Princeton, NJ, USA. Electronic address: zheming.ruan@bms.com.
